SYNPR

Across TCGA pan-cancer cohorts, SYNPR Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SYNPR data layer compared with 17 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SYNPR Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SYNPR expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

STAD, LUSC, and DLBC are the cancer types where SYNPR Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.184	0.730	.001	33	view →
LUSC	OS	Median	II,III,IV	0.168	0.632	.008	21	view →
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
MESO	DFS	Median	II,III,IV	0.039	0.407	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	All	0.221	0.799	.022	6	view →
SKCM	OS	Median	II,III,IV	0.233	0.739	.020	3	view →
GBM	DFS	Median	All	1.000	0.192	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SYNPR–STAD (OS)

Open the STAD breakdown →